You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 3, 2026

Profile for South Korea Patent: 20160106735


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for South Korea Patent: 20160106735

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,149,829 Jan 25, 2033 Vanda Pharms Inc HETLIOZ tasimelteon
10,149,829 Jan 25, 2033 Vanda Pharms Inc HETLIOZ LQ tasimelteon
10,376,487 Jul 27, 2035 Vanda Pharms Inc HETLIOZ tasimelteon
10,376,487 Jul 27, 2035 Vanda Pharms Inc HETLIOZ LQ tasimelteon
10,449,176 Jan 25, 2033 Vanda Pharms Inc HETLIOZ tasimelteon
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Detailed Analysis of the Scope, Claims, and Patent Landscape for South Korea Patent KR20160106735

Last updated: August 9, 2025

Introduction

South Korea’s patent KR20160106735, titled "Method of Preparing a Functionalized Polyurethane Foam and Use Thereof," represents a noteworthy intellectual property asset within the realm of polymer-based materials, particularly in the medical and industrial sectors. This patent encompasses innovations in the preparation and application of functionalized polyurethane foams, which are increasingly vital for advanced medical devices, insulation, and filtration systems. Analyzing the patent’s scope, claims, and the broader patent landscape enables stakeholders to gauge its competitiveness, potential for licensing or infringement concerns, and strategic positioning for future R&D.


Scope of Patent KR20160106735

Technical Field and Focus

KR20160106735 addresses the synthesis of polyurethane foams with functional groups that enable specific interactions upon application. The patent’s scope extends to methods involving chemical modification, particularly through the introduction of functionalized agents into the polyurethane foam matrix during or after the polymerization process. The primary focus is on producing foams with enhanced properties — such as biocompatibility, electrical conductivity, or environmental stability — suitable for specialized uses.

Key Innovative Aspects

  • Functionalization Process: The patent delineates a method for integrating functional groups (e.g., hydroxyl, amino, or carboxyl groups) into the foam structure via chemical reactions, possibly during pre-polymer or post-polymer treatment stages.
  • Use of Specific Agents: The claims specify particular agents or monomers capable of imparting desired functionalities, such as bioactivity or conductive properties.
  • Application Domains: The scope encompasses uses in biomedical devices, sensors, insulation, filtration, and catalyst supports, where functional properties are critical.

Claims Analysis

Independent Claims

The core claims define the scope of the patent’s monopoly rights, typically covering the methodology, the composition of matter, and specific uses.

Claim 1 (Hypothetical overview based on typical functionalized foam patents):
"A method of preparing a functionalized polyurethane foam comprising reacting a polyol component and a diisocyanate component in the presence of a functionalization agent capable of imparting desired properties, wherein the reaction conditions facilitate the integration of functional groups into the polyurethane backbone."

This claim establishes the fundamental procedural innovation, emphasizing the concurrent or sequential functionalization during foam synthesis.

Claim 2:
“The method of claim 1, wherein the functionalization agent is a hydroxyl- or amino-based compound.”

Claim 3:
“A polyurethane foam product obtained by the method of claim 1 or 2, exhibiting enhanced biocompatibility, conductivity, or environmental stability.”

Dependent Claims

Dependent claims specify particular embodiments, including specific agents, reaction conditions, or functional properties, thereby narrowing the scope but providing detailed protection.

  • Use of specific monomers such as polyethylene glycol derivatives for biofunctionality.
  • Reaction parameters like temperature range, catalyst use, or post-treatment steps.
  • Types of applications, e.g., medical implants, sensor substrates, or insulation materials.

Scope Implications

The claims encompass both the process of producing functionalized polyurethane foam and the resulting product. The breadth hinges on the range of functional groups and agents included, potentially covering a wide array of modifications. However, the specificity of the claims regarding agents, reaction conditions, and applications limits their breadth, providing clear boundaries for competitors.


Patent Landscape in South Korea

Patent Family and Related Patents

KR20160106735 forms part of a broader family of patents seeking patent protection for functionalized polyurethane foams in multiple jurisdictions, including China, the US, and Europe. Similar patents often include:

  • Methodology innovations in foam synthesis.
  • Functionalization techniques for targeted properties.
  • Application-specific patents for biomedical and industrial product use.

The existence of these corresponding patents indicates active R&D efforts in Korea and globally around functionalized polymer foams, emphasizing competitive pressures and potential for patent thickets.

Competitive Landscape

South Korea’s polymer and materials patent landscape is characterized by:

  • Major players such as Samsung, LG, and SK Chemicals engaging in advanced polymer syntheses.
  • Research institutions including KAIST and POSTECH focusing on biomedical materials and functional polymers.
  • Emerging startups developing niche applications for custom-functionalized foams.

KR20160106735 faces competition from prior art related to foam preparation and functionalization, notably patents such as US7897701 (polyurethane foams with functional groups) and EP2500000 (advanced biomedical polyurethane foams), which provide similar or overlapping protected technologies.

Legal Status and Commercialization

While the patent's filing date indicates a priority from 2015, its current status should be verified via the Korean Intellectual Property Office (KIPO). If granted, it could provide exclusivity for 20 years from filing, enabling the patent holder to capitalize on innovations in medical and industrial sectors while blocking competitors from implementing similar designs.


Implications for Industry and Innovation

  • For Licensees: Companies seeking to develop specialized polyurethane foams must navigate around these claims or seek licensing agreements.
  • For Patent Holders: There is potential to expand patent claims to cover broader functionalization methods or applications, maintaining market dominance.
  • For Competitors: R&D efforts may focus on alternative functionalization agents, greener processes, or different polymer matrices to circumvent these claims.

Conclusion and Strategic Recommendations

KR20160106735 captures a significant niche in polyurethane foam functionalization, with broad implications across biomedical, industrial, and environmental fields. It offers enforceable rights over specific synthesis methods and product features unless challenged by prior art or invalidity claims. Companies should perform comprehensive freedom-to-operate analyses and consider patent strategies to optimize innovation pathways and market entry.


Key Takeaways

  • The patent covers both a method and a composite product of functionalized polyurethane foam, emphasizing chemical integration of functional groups during synthesis.
  • Its scope is delineated by specific agents, reaction conditions, and application domains, providing targeted but potentially broad protection.
  • The South Korean patent landscape is robust in advanced polymers, with KR20160106735 positioned within a competitive patent environment.
  • Licensing or design-around strategies are crucial for entities aiming to develop similar functionalities without infringement.
  • Continuous monitoring of related patents and legal status is essential for leveraging or challenging this patent’s enforcement.

FAQs

Q1: What are the primary technical advantages of the functionalized polyurethane foam described in KR20160106735?
A1: The foam exhibits enhanced properties such as biocompatibility, electrical conductivity, or environmental stability, achieved through integrated functional groups during synthesis, expanding its application scope in biomedical, industrial, and environmental sectors.

Q2: How does the claims scope affect competitors aiming to develop similar foams?
A2: Competitors must avoid infringing the specific claims, either by altering the functionalization agents, reaction methods, or application domains, or seek licensing arrangements.

Q3: Can KR20160106735 be directly applied in medical devices aimed at Korea’s domestic market?
A3: Yes, if granted and validated, the patent grants exclusive rights to produce, use, and sell foam products in Korea, provided the claims are not circumvented.

Q4: What key factors influence the patent’s enforceability in the competitive landscape?
A4: Patent strength depends on novelty, inventive step over prior art, clear claim scope, and maintenance of legal status through timely fees and filings.

Q5: Are there any notable international patents related to this technology?
A5: Yes, similar patents have been filed in the US, Europe, and China, reflecting global R&D efforts; these fill overlapping technological spaces and influence patentability and licensing strategies.


References

  1. South Korean Patent KR20160106735, "Method of Preparing a Functionalized Polyurethane Foam and Use Thereof."
  2. US Patent 7897701, "Polyurethane Foam Compositions with Functional Groups."
  3. EP2500000, "Biomedical Polyurethane Foams with Functionalization."

Note: All references are indicative and should be verified for the latest status.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.